A comprehensive PGx portfolio designed to deliver the results you need

Pharmacogenomics (PGx) is an exciting and powerful emerging field that promises to improve health care outcomes. PGx helps provide meaningful data that can help prevent adverse drug reactions and lower medical costs. When you partner with us, you gain access to a wide range of PGx genotyping solutions and the vast expertise we’ve acquired from a decade of driving advancements in PGx.

PGx research is part of the ongoing effort to tailor results to the individual by taking into account their genome, lifestyle, and other attributes. Like blood typing research before it, PGx research aims to avoid mismatches between individual cases and their respective approaches.

The future of health care includes factoring genetic test results into decisions.

Not sure where to begin? We can help you identify your testing requirements and make it easy for you to pick the right technology based on whether you need genotyping, copy number variation (CNV), and/or human leukocyte antigen (HLA) analysis.

Have content questions? We have carefully curated fixed content or flexible custom options, which will also guide your technology selection. We’re also here to help establish your workflow so that whether you’re testing for one target or 4,000, your lab is set up for success from the beginning. Rest assured that we continue to invest in developing innovative technologies that draw from our global network of specialists to make PGx accessible and affordable.


Get to know our products using the selection guide below or by contacting our team

Real-time PCR 

A flexible, scalable, and qualified solution for routine testing and more. Real-time PCR is optimal for routine testing and preemptive analysis using actionable genetic markers.

Learn more ›

Next-generation sequencing

High-performance variant discovery and annotated biomarker analysis using our targeted Ion AmpliSeq PGx Community Panel.

Learn more ›


With the maximum amount of data available from samples, the Applied Biosystems PharmacoScan and PharmacoFocus microarray solutions are best positioned for research and development and preemptive analysis of all known markers.

Learn more ›


Which solution is right for me?



Real-time PCR Next-generation sequencingMicroarray


TaqMan SNP Genotyping Assays including OpenArray format

Ion AmpliSeq technology

PharmacoScan and PharmacoFocus Solutions


Genotyping, CNV*

Genotyping, CNV

Genotyping, CNV, HLA

Number of targets

Up to 120 targets

>130 targets in 40 genes

PharmacoScan: ~4,500 targets in ~1,000 genes
PharmacoFocus: ~2,000 targets in 150 genes

Time to result

5 hours

2 days

~3 days

Other features

  • Low-cost per sample
  • Fast time to result
  • Scalable, from single gene to panel screening
  • Qualified solution with over 7 million samples tested to date, launched in 2012
  • Optimized targeted sequencing with powerful Ion AmpliSeq technology
  • Analysis of annotated variants
  • New variant discovery
  • Maximum data available
  • Cost-effective, reproducible, and scalable solution for translational researchers
  • Offers genotyping, CNV, and HLA in a single workflow
  • Integrated star alleles with metabolizer status

*Application supported via separate workflow

Featured news, events, and blogs


The State of Pharmacogenomics: A Panel Discussion About the Future of Pharmacogenetic Testing and Personalized Medicine

Top PGx thought leaders gathered to discuss the future of PGx testing and personalized medicine.


Improve Lives, Reduce Costs and Simplify Decision-Making: Enterprise Pharmacogenomics

Dr. Jeffrey Shaman, Chief Science Officer at Coriell Life Sciences shares how PGx can enhance current wellness and medication risk management programs.


White paper: PGx improves health system performance

Bruce Quinn and Associates, February 2018.


Article: Practicing pharmacogenomics at scale

Read about Thermo Fisher Scientific's pharmacogenomics partnership with UPMC/University of Pittsburgh.

Video: Pharmacogenomics ready for mainstream

Hear how Coriell Life Sciences, the Personalized Medicine Coalition, and other precision medicine experts discuss the progress made in pharmacogenomics.


  1. An-Economic-Evaluation-of-Pharmacogenomic-Testing.pdf (pro-genex.com)
  2. Maciel A, Cullers A, Lukowiak AA, Garces J (2018) Estimating cost savings of pharmacogenetic testing for depression in real-world clinical settings. Neuropsychiatric disease and treatment 14: 225–230. https://doi. org/10.2147/NDT.S145046


For Research Use Only. Not for use in diagnostic procedures.

Style Sheet for Global Design System